Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has entered into a...
Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition
Germany-based multinational Merck KGaA (ETR: MRK) reported Q2 2025 financial results, which were significantly affected...
Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
China-based Akeso Biopharma (HKG: 9926) announced that the first patient has been enrolled in the phase...
Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced on August 8, 2025, that its self-developed...
Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment
German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...
Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets
China-based Lepu Biopharma Co., Ltd. (HKG: 2157) announced on August 1, 2025, that it has...
Tigermed Partners with Africare BioPharma to Enhance Africa’s Clinical Research Capabilities
On August 8, 2025, Hangzhou Tigermed Consulting (SHE: 300347, HKG: 3347), a China-based contract research...
Johnson & Johnson’s Rybrevant Approved by China’s NMPA for EGFR-Mutant NSCLC Treatment
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that China’s National Medical Products Administration...
Bio-Thera Solutions Receives NMPA Approval for Combination Therapy Clinical Trial in Advanced Solid Tumors
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced that it has received a Drug Clinical Trial...
Viatris Reports Q2 Revenue Drop, Sees Growth in Greater China Amid Global Decline
US-based generics firm Viatris Inc. (NASDAQ: VTRS) reported Q2 2025 financial results, showing a 7%...
Jingxin Pharma Signs Patent License for Cariprazine Hydrochloride With Gedeon Richter
China-based Jingxin Pharmaceutical Co., Ltd. (SHE: 002020) announced that it has signed a Patent License...
Teleflex’s Rüsch EZ-Blocker Gets NMPA Approval for China Market
US-based Teleflex Incorporated (NYSE: TFX) announced that its Rüsch EZ-Blocker single-use bronchial blocker has received...
Tellgen Plans Acquisition of 82% Stake in Wuhan HealthCare Biotech for RMB 328 Million
China-based Tellgen Corporation (SHE: 300642) announced plans to acquire an 82.00% stake in Wuhan HealthCare...
Haisco’s HSK47388 Receives NMPA Clinical Trial Approval for Autoimmune Diseases
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
HutchMed Reports 9% Revenue Dip in H1 2025; FRUZAQLA Sales Grow Despite Overall Decline
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced its financial results for...
Westgene Partners with BGI Huo-Yan for mRNA Drug Development and Industrialization
Chengdu Westgene Biopharma announced the establishment of a strategic partnership with Shenzhen BGI Huo-Yan Engineering...
Henlius’ HLX43 Approved by FDA for Phase 1 Trial in Thymic Carcinoma Treatment
China’s Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the U.S. Food and Drug Administration...
Cryofocus Medtech’s Cryoadhesion System Gains NMPA Approval for Commercialization
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced that it has received approval from China’s...
Zai Lab Announces Q2 2025 Results With 10% Revenue Growth Driven by Key Products
China-based biotech Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced its financial results for the...